Revagenix

Series-B
revagenix.com Biotech & Healthcare
Total Funding Undisclosed
Latest Round Undisclosed Series-B
Last Announced Jan 5, 2024
Investors Undisclosed
Decision Makers 6 Available

About Revagenix

Revagenix engineers precision therapies for serious chronic disease. Our lead program, Rev-56, is an inhaled therapy entering Phase 1 for non-CF bronchiectasis.

Sectors & Market Categories

Company Details

Intelligence Dossier

Corporate & Operational Profile

Primary Industry Biotech & Healthcare
Funding Stage Series-B
Global Headquarters Undisclosed
Tracked Since Nov 8, 2026

Web & Domain Identity

Official Website revagenix.com
Domain Registered Date Undisclosed

Social & Network Presence

X / Twitter Profile Not linked
LinkedIn Corporate Not linked

Company Milestones & Timeline

1 Events
  1. Capital Raise

    Raised undisclosed · Series-B

    fundraisingfox.com

Investors & Backers

Investor firms and individual backers were not publicly disclosed in available round filings for Revagenix.

Funding History

1 Round
Series-B equity · Jan 5, 2024

Founders & Leadership

2

Andrew McCandlish

Co-founder & COO

Work email & phone locked Unlock →

Ryan Cirz

Co-founder & CEO

Work email & phone locked Unlock →

Press Coverage & Sources

Recently Funded Biotech & Healthcare Startups

View all

Search the startup feeds free with 50 starter credits.

Recently funded startups
New SaaS launches
Never pay twice for contacts